Evotec looks to China for first development deal for anti-inflammatory candidate
This article was originally published in Scrip
Executive Summary
Evotec of Germany has granted the Chinese company Conba Pharmaceutical development and marketing rights in China to EVT 401, a selective, small molecule P2X7 antagonist, for human indications with the exception of ophthalmological disorders, chronic obstructive pulmonary disease (COPD) and endometriosis.